301075 Stock Overview
Tibet Duo Rui Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations and its raw materials in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 1/6 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥19.50 |
52 Week High | CN¥35.54 |
52 Week Low | CN¥12.60 |
Beta | -0.29 |
1 Month Change | -8.28% |
3 Month Change | 5.81% |
1 Year Change | -22.71% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -56.58% |
Recent News & Updates
Shareholder Returns
301075 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 6.0% | 4.2% | 2.9% |
1Y | -22.7% | -12.8% | -13.2% |
Return vs Industry: 301075 underperformed the CN Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: 301075 underperformed the CN Market which returned -13.2% over the past year.
Price Volatility
301075 volatility | |
---|---|
301075 Average Weekly Movement | 12.4% |
Pharmaceuticals Industry Average Movement | 7.3% |
Market Average Movement | 8.5% |
10% most volatile stocks in CN Market | 12.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 301075's share price has been volatile over the past 3 months.
Volatility Over Time: 301075's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 395 | Yong Deng | www.duoruiyy.com |
Tibet Duo Rui Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations and its raw materials in China. It offers fluid therapy, anesthesiology, analgesic, and first-aid medication products.
Tibet Duo Rui Pharmaceutical Co., Ltd. Fundamentals Summary
301075 fundamental statistics | |
---|---|
Market cap | CN¥1.56b |
Earnings (TTM) | CN¥18.73m |
Revenue (TTM) | CN¥334.67m |
83.3x
P/E Ratio4.7x
P/S RatioIs 301075 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301075 income statement (TTM) | |
---|---|
Revenue | CN¥334.67m |
Cost of Revenue | CN¥126.14m |
Gross Profit | CN¥208.54m |
Other Expenses | CN¥189.80m |
Earnings | CN¥18.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.23 |
Gross Margin | 62.31% |
Net Profit Margin | 5.60% |
Debt/Equity Ratio | 34.4% |
How did 301075 perform over the long term?
See historical performance and comparison